FDA
-
-
-
-
-
-
-
FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's
-
-
-
-
-
-
-
Stoke Therapeutics names Thomas McCauley as chief scientific officer
-
-
-
-
-
-
-
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
-
-
-
-
-
-
-
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
-
-
-
-
-
-
-
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
-
-
-
-
-
-
-
FDA approves high dose SPINRAZA for spinal muscular atrophy
-
-
-
-
-
-
-
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
-
329,543 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

